Cathie Wood's Ark Invest Boosts Gene-Editing Holdings, Sells $30M in Tesla Stock

Cathie Wood's Ark Invest has increased exposure to gene-editing companies, including CRISPR Therapeutics, and autonomous mobility companies, while further reducing holdings in Tesla and Rocket Lab. The firm has bought $8.8 billion worth of shares in CRISPR Therapeutics and has reduced its Tesla holdings by $30 million. Ark Invest has also increased its exposure to autonomous mobility companies.